301 results on '"Matsushita, Yuto"'
Search Results
2. The efficacy of second-line tyrosine kinase inhibitor for patients with metastatic non-clear cell renal cell carcinoma following first-line immune-oncology combination therapy
3. Comparative assessment of disease recurrence after transurethral resection of non-muscle-invasive bladder cancer with and without a photodynamic diagnosis using 5-aminolevulinic acid: a propensity score-matching analysis
4. Comparison of Cabozantinib and Axitinib as Second-line Therapy After Nivolumab Plus Ipilimumab in Patients With Metastatic Clear Cell Renal Cell Carcinoma: A Comparative Analysis of Retrospective Real-world Data
5. Efficacy and safety of second-line cabozantinib after immuno-oncology combination therapy for advanced renal cell carcinoma: Japanese multicenter retrospective study
6. Assessments of therapeutic effects according to timings for combined therapy with axitinib and immune check point inhibitor in a mouse renal cell carcinoma model
7. Development of a Simple and Objective Prognostication Model for Patients with Advanced Solid Malignant Tumors Treated with Immune Checkpoint Inhibitors: A Pan-Cancer Analysis
8. Prognostic impact of histological discordance between transurethral resection and radical cystectomy.
9. Photodynamic diagnosis‐assisted transurethral resection of bladder tumor for high‐risk non‐muscle invasive bladder cancer improves intravesical recurrence‐free survival (BRIGHT study).
10. Differences in oncological benefits from second transurethral resection between white‐light initial surgery and photodynamic diagnosis‐guided initial surgery for primary high‐risk non‐muscle invasive bladder cancer.
11. Assessment of Therapeutic Effects of Combined Treatment With Cisplatin and Anti-mouse Programmed Death (PD)-1 Antibody in a Mouse Urothelial Cancer Model
12. Clinical outcomes in patients with advanced urothelial carcinoma treated with enfortumab vedotin: A retrospective multicenter study in Japan
13. Relationship Between Adverse Events and Progression-free Survival in Patients Receiving Cabozantinib for Previously Treated Metastatic Renal Cell Carcinoma
14. Prognostic significance of third-line treatment for patients with metastatic castration-resistant prostate cancer: comparative assessments between cabazitaxel and other agents
15. Preoperative factors predicting poor therapeutic efficacy of holmium laser enucleation of the prostate in patients with benign prostatic hyperplasia.
16. Prognostic outcomes in patients with metastatic renal cell carcinoma receiving second‐line treatment with tyrosine kinase inhibitor following first‐line immune‐oncology combination therapy.
17. Robot-assisted radical nephroureterectomy for upper urinary tract tumor: initial experience with the use of novel surgical robot system, hinotori
18. Robot‐assisted radical nephrectomy and inferior vena cava tumor thrombectomy using the novel surgical robot platform, hinotori: Initial experience with two cases
19. The impact of second transurethral resection on survival outcomes in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette–Guérin therapy
20. Second-line Pembrolizumab for Metastatic Urothelial Carcinoma: Differences in Treatment Outcomes According to the Primary Site
21. A DNA adductome analysis revealed a reduction in the global level of C5-hydroxymethyl-2′-deoxycytidine in the non-tumoral upper urinary tract mucosa of urothelial carcinoma patients
22. Mass spectrometric profiling of DNA adducts in the human stomach associated with damage from environmental factors
23. Improved perioperative outcomes by early unclamping prior to renorrhaphy compared with conventional clamping during robot-assisted partial nephrectomy: a propensity score matching analysis
24. Robot‐assisted radical nephrectomy and inferior vena cava tumor thrombectomy using the novel surgical robot platform, hinotori: Initial experience with two cases.
25. The impact of second transurethral resection on survival outcomes in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette–Guérin therapy.
26. Robot‐assisted radical nephrectomy using novel surgical robot platform, hinotori: Report of initial series of 13 cases
27. Impact on Japanese healthcare economics of photodynamic diagnosis‐assisted transurethral resection of bladder tumor for non‐muscle invasive bladder cancer: A multicenter retrospective cohort study
28. Comparison of Alternative Androgen Receptor-axis-targeted Agent (ARATA) and Docetaxel as Second-line Therapy for Patients With Metastatic Castration-resistant Prostate Cancer With Progression After Initial ARATA in Real-world Clinical Practice in Japan
29. Comparative assessment of prognostic outcomes between first-generation antiandrogens and novel androgen-receptor-axis-targeted agents in patients with non-metastatic castration-resistant prostate cancer
30. Marked response to nivolumab combined with external radiation therapy for metastatic renal cell carcinoma: report of two cases
31. Perioperative outcomes of robot-assisted partial nephrectomy using hinotori versus da Vinci surgical robot system: a propensity score-matched analysis
32. Robot‐assisted adrenalectomy using a hinotori surgical robot system: Report of first series of six cases
33. Optimal Time Point for Evaluation of Response to Pembrolizumab Treatment in Japanese Patients With Metastatic Urothelial Carcinoma
34. Initial Experience of Robot-Assisted Partial Nephrectomy Using Hinotori Surgical Robot System: Single Institutional Prospective Assessment of Perioperative Outcomes in 30 Cases
35. Significant impact of three-dimensional volumetry of perinephric fat on the console time during robot-assisted partial nephrectomy
36. Oncological outcomes after cytoreductive nephrectomy for patients with metastatic renal cell carcinoma with inferior vena caval tumor thrombus
37. No significant impact of response to prior androgen receptor-axis-targeted agents on the efficacy of subsequent docetaxel in patients with metastatic castration-resistant prostate cancer
38. Efficacy and safety of pembrolizumab and axitinib as first‐line treatment for patients with advanced renal cell carcinoma: Real‐world experience in Japan.
39. Significance of second progression‐free survival in patients with advanced urothelial cancer who received platinum‐based combination chemotherapy followed by pembrolizumab.
40. Additional oncological benefit of photodynamic diagnosis with blue light cystoscopy in transurethral resection for primary non‐muscle‐invasive bladder cancer: A comparative study from experienced institutes
41. Significance of second progression‐free survival in patients with advanced urothelial cancer who received platinum‐based combination chemotherapy followed by pembrolizumab
42. Predictive factors of de novo overactive bladder in clinically localized prostate cancer patients after robot‐assisted radical prostatectomy
43. No significant impact of prior treatment profile with docetaxel on the efficacy of cabazitaxel in Japanese patients with metastatic castration-resistant prostate cancer
44. The Association of Tumor Immune Microenvironment of the Primary Lesion with Time to Metastasis in Patients with Renal Cell Carcinoma: A Retrospective Analysis
45. Association of Increased Age With Decreased Response to Intravesical Instillation of Bacille Calmette-Guérin in Patients With High-Risk Non-Muscle Invasive Bladder Cancer: Retrospective Multi-Institute Results From the Japanese Urological Oncology Research Group JUOG-UC-1901-BCG
46. Assessments of optimal timing for combined therapy with axitinib and immune check point inhibitor in a mouse renal cell carcinoma model
47. Validation of the risk stratification newly defined in the Japanese Urological Association guidelines 2019 for non‐muscle invasive bladder cancer: A multi‐institutional collaborative study.
48. Real‐world treatment patterns and oncological outcomes in early relapse and refractory disease after bacillus Calmette‐Guérin failure in non‐muscle‐invasive bladder cancer
49. Abstract 2257: DNA adductome analysis in human colorectal tissues
50. Risk stratification for the prognosis of patients with chemoresistant urothelial cancer treated with pembrolizumab
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.